Lipoprotein(a): Its relevance to the pediatric population

Catherine J McNeal1

  • 1Division of Cardiology, Department of Internal Medicine, Baylor Scott & White Health, Temple, TX, USA.

Insights

Lipoprotein(a) (Lp(a)) is a key risk factor for cardiovascular disease in children, appearing early in life. Current guidelines don't recommend routine Lp(a) screening due to limited evidence on treatment effectiveness.

Area of Science:

  • Cardiovascular Science
  • Pediatric Cardiology
  • Lipid Metabolism

Background:

  • Lipoprotein(a) (Lp(a)) is an inherited, highly atherogenic lipoprotein.
  • Unlike other lipoproteins, Lp(a) levels are established early in childhood.
  • Lp(a) is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD).

Purpose of the Study:

  • To review the significance of Lp(a) in pediatric ASCVD risk.
  • To discuss current guidelines regarding Lp(a) screening in youth.
  • To highlight the need for lifestyle modifications to mitigate ASCVD risk in children.

Main Methods:

  • Literature review of Lp(a) metabolism and clinical significance in pediatrics.
  • Analysis of current pediatric cardiovascular health guidelines.
  • Discussion of Lp(a) risk factors and management strategies.

Main Results:

  • Lp(a) is expressed early in life and is a significant ASCVD risk factor.
  • Routine Lp(a) screening is not recommended except for specific high-risk pediatric groups.
  • Data on the efficacy of lowering Lp(a) to reduce ASCVD risk is limited.
  • Lp(a) elevation significantly increases the risk of arterial ischemic stroke in children.

Conclusions:

  • Lp(a) poses a substantial cardiovascular risk in children, necessitating awareness.
  • While specific treatments are lacking, managing modifiable risk factors is crucial.
  • Education on Lp(a) risks and preventive lifestyle choices is vital for pediatric cardiovascular health.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
482
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
377
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
750
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
337
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
849
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
417